Health Expenditures

El sistema sanitario y la inmigración en España desde la perspectiva de la política fiscal

Economics / Primary Health Care / Economic Development / Public Health / Spain / Public expenditure / Social Welfare / Humans / Health Services / Population Growth / Health System / Health Expenditures / Public Service / Fertility Rate / Geographic distribution / Universal Access / Health Expenditure / Public expenditure / Social Welfare / Humans / Health Services / Population Growth / Health System / Health Expenditures / Public Service / Fertility Rate / Geographic distribution / Universal Access / Health Expenditure

El sistema sanitario y la inmigración en España desde la perspectiva de la política fiscal

Economics / Primary Health Care / Economic Development / Public Health / Spain / Public expenditure / Social Welfare / Humans / Health Services / Population Growth / Health System / Health Expenditures / Public Service / Fertility Rate / Geographic distribution / Universal Access / Health Expenditure / Public expenditure / Social Welfare / Humans / Health Services / Population Growth / Health System / Health Expenditures / Public Service / Fertility Rate / Geographic distribution / Universal Access / Health Expenditure

Distribución del gasto sanitario en atención primaria según edad y sexo: un análisis retrospectivo

Primary Care / Primary Health Care / Adolescent / Spain / Humans / Child / Female / Male / Young Adult / Infant / Clinical Sciences / Aged / Middle Aged / Health Expenditures / Adult / Retrospective Studies / Atencion Primaria De La Salud / Age Groups / Health Expenditure / Child / Female / Male / Young Adult / Infant / Clinical Sciences / Aged / Middle Aged / Health Expenditures / Adult / Retrospective Studies / Atencion Primaria De La Salud / Age Groups / Health Expenditure

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Costes directos sanitarios en pacientes con diabetes mellitus tipo 2 a los seis meses de inicio del tratamiento con insulina en España: estudio INSTIGATE

Treatment Outcome / Comorbidity / Spain / Prospective studies / Humans / Blood Glucose / Insulin / Diabetes mellitus / Europe / Hospitalization / Female / Male / Aged / Middle Aged / Health Expenditures / Oral Hypoglycemic Agents / Drug Costs / Combination drug therapy / Type 2 Diabetes Mellitus / Prospective Study / Blood Glucose / Insulin / Diabetes mellitus / Europe / Hospitalization / Female / Male / Aged / Middle Aged / Health Expenditures / Oral Hypoglycemic Agents / Drug Costs / Combination drug therapy / Type 2 Diabetes Mellitus / Prospective Study

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH)

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH)

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2013 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana

Expert testimony / Clinical Trial / Medical Microbiology / Treatment Outcome / Spain / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic / Decision Trees / Antiretroviral Therapy / Humans / Therapy / Hiv Infection / Cost effectiveness / Efficiency / Health Expenditures / Theoretical Models / Genotype / Adult / Economic Models / Cost Benefit Analysis / Highly Active Antiretroviral Therapy / Drug Costs / Combination drug therapy / Disease Management / Clinical Protocols / Acquired immunodeficiency syndrome / Viral Load / Clinical Trials as Topic

Type 2 diabetes mellitus in China: a preventable economic burden

China / Public Health / Humans / Female / Male / Aged / Middle Aged / Health Expenditures / Adult / Public health systems and services research / Cost Benefit Analysis / Health surveys / Health Care Costs / Type 2 Diabetes Mellitus / Cross Sectional Studies / The American / Aged / Middle Aged / Health Expenditures / Adult / Public health systems and services research / Cost Benefit Analysis / Health surveys / Health Care Costs / Type 2 Diabetes Mellitus / Cross Sectional Studies / The American

La interacción del sistema social y el sanitario. Informe SESPAS 2012

Demography / Social Work / Health Promotion / Rehabilitation / Health Care / Adolescent / Spain / Humans / Child / Europe / Female / Male / Universal Coverage / Young Adult / Infant / Caregivers / Aged / Middle Aged / Health Expenditures / Adult / Integrated Care / Home Care Services / Personal autonomy / Disabled Persons / Adolescent / Spain / Humans / Child / Europe / Female / Male / Universal Coverage / Young Adult / Infant / Caregivers / Aged / Middle Aged / Health Expenditures / Adult / Integrated Care / Home Care Services / Personal autonomy / Disabled Persons

Costos directos de varicela complicada en una población pediátrica de Colombia

Colombia / Humans / Child / Hospital costs / Infant / Diagnostic Imaging / Length of Stay / Newborn Infant / Health Expenditures / Retrospective Studies / Drug Costs / Chickenpox / Diagnostic Imaging / Length of Stay / Newborn Infant / Health Expenditures / Retrospective Studies / Drug Costs / Chickenpox

El gasto que está triste y azul. Debe preocupar más la salud que el gasto sanitario

Economics / Public Health / Health Policy / Spain / Health Care reform / Health Care Rationing / Health Expenditures / Budgets / Cost Savings / Gross Domestic Product (GDP) / Health Care Rationing / Health Expenditures / Budgets / Cost Savings / Gross Domestic Product (GDP)

Un análisis del gasto público en salud de los entes territoriales colombianos

Public Health / Health Systems / Health Expenditures / Universal Health Coverage

Distribución del gasto sanitario en atención primaria según edad y sexo: un análisis retrospectivo

Primary Care / Primary Health Care / Adolescent / Spain / Humans / Child / Female / Male / Young Adult / Infant / Clinical Sciences / Aged / Middle Aged / Health Expenditures / Adult / Retrospective Studies / Atencion Primaria De La Salud / Age Groups / Health Expenditure / Child / Female / Male / Young Adult / Infant / Clinical Sciences / Aged / Middle Aged / Health Expenditures / Adult / Retrospective Studies / Atencion Primaria De La Salud / Age Groups / Health Expenditure
Copyright © 2017 DATOSPDF Inc.